Researchers found that C2N Diagnostics’ PrecivityAD2 blood test improved healthcare providers’ ability to assess the likelihood of Alzheimer’s disease in their patients. This improved accuracy led to more informed decisions regarding treatment, including changes in Alzheimer’s medication plans and further brain amyloid testing. The study involved diverse patient demographics, including underrepresented minorities, and took place across various academic and community-based practices.

This advancement is crucial because early and accurate Alzheimer’s diagnosis is a significant unmet need. The PrecivityAD2 test offers a less invasive and more accessible alternative to traditional diagnostic methods like cerebrospinal fluid analysis or PET scans. This improved accessibility could lead to earlier diagnosis, allowing patients and their families to make informed decisions about care and future planning sooner. It also facilitates earlier intervention with potential disease-modifying therapies, maximizing their effectiveness.

The Quality Improvement PrecivityAD2 (QUIP II) study involved 12 memory specialists treating 203 patients with cognitive impairment symptoms. The study focused on clinician-reported changes in diagnostic certainty and subsequent patient management plans before and after using the blood test. The results revealed a notable increase in diagnostic confidence and corresponding adjustments in treatment strategies after utilizing the PrecivityAD2 test. The test demonstrated over 90% accuracy compared to traditional methods. Furthermore, this builds on previous research demonstrating the test’s efficacy, particularly in primary care settings, and reinforces earlier findings from the QUIP I study on the PrecivityAD test.

The positive results from the QUIP II study strengthen the case for broader adoption of blood biomarker tests like PrecivityAD2 in Alzheimer’s disease diagnosis and management. This could lead to a paradigm shift in how Alzheimer’s is diagnosed, potentially streamlining the diagnostic process and improving patient outcomes. Increased access to accurate and convenient diagnostic tools may also stimulate further research and development of effective treatments and preventative strategies for Alzheimer’s disease.

Source link: http://www.businesswire.com/news/home/20250131274747/en/Study-Highlights-How-C2N%E2%80%99s-PrecivityAD2%E2%84%A2-Blood-Biomarker-Test-Use-Improves-Clinical-Decision-Making-in-the-Evaluation-for-Alzheimer%E2%80%99s-Disease

+ posts

Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.